AACOMmunities

Federal Funding Opportunities and Resources

Below is a selected list of timely federal funding opportunities that are relevant to the osteopathic medical education community. AACOM updates this resource frequently.  Please bookmark the page for your reference. For a comprehensive listing of federal funding opportunities, please visit Grants.gov.   

The U.S. Department of Health and Human Services (HHS) has developed a Grant Opportunities and Guidance clearinghouse across all departments where you can find information about all aspects of the grant process during the COVID-19 crisis. For example, the NIH webpage provides  information and guidance about extensions, resubmissions, and funding opportunities related to COVID-19.  Its resources are also presented here, in a daily, updated format.

 

Featured Opportunities

 

September 4-17, 2021

National Institutes of Health

Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)
Application Due Dates: October 16, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to enhance the diversity of the mental health research workforce by providing dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from groups underrepresented in biomedical, behavioral, clinical and social sciences research.

NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical Trial Not Allowed)
Application Due Dates: October 12, 2021
This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities.

NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)
NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)

Application Due Dates: October 12, 2021
This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences.

Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)
Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)

Application Due Dates: October 12, 2021
This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
Application Due Dates: January 07, 2022
This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources.

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: February 15, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD).

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: November 12, 2021

Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: November 18, 2021
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes.

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)

Letter of Intent Due Date(s): October 15, 2021
Application Due Dates: November 15, 2021
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is soliciting applications for the Pancreatic Cancer Detection Consortium (PCDC). The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma and conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer.

Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): October 19, 2021
Application Due Dates: November 19, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate a high-resolution, high-content, multiscale atlas of a non-diseased human organ. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration,analysis and interpretation.

The Human BioMolecular Atlas Program (HuBMAP) Demonstration Project (U01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): October 19, 2021
Application Due Dates: November 19, 2021
The goal of this funding opportunity announcement is to solicit applications that will creatively use datasets and resources from the Human BioMolecular Atlas Program (HuBMAP: https://commonfund.nih.gov/hubmap) to demonstrate their use to address significant biomedical and biological questions.

Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: December 09, 2021
This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system function and disorders throughout life, relevant to LMICs.

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional)
Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional)

Letter of Intent Due Date(s): January 09, 2022
Application Due Dates: February 09, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ9-tetrahydrocannabinol (THC) that is present in cannabis and cannabis products.

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: February 11, 2022
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial.

August 21 - Sept 3, 2021

Health Resources and Services Administration

Service Area Competition
Application Due Dates: November 01, 2021
This notice announces the opportunity to apply for funding under the Health Center Program’s Service Area Competition (SAC). The Health Center Program supports domestic public or private, nonprofit community-based and patient-directed organizations that provide primary health care services to the Nation’s medically underserved populations.

Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance
Application Due Date: November 22, 2021
The purpose of this funding is to build the capacity of ADAPs through tools and technical assistance to maximize the impact of ADAPs in improving the health outcomes of people with HIV in a changing health care environment.

National Institutes of Health

Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)
Application Due Dates: October 16, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI).

NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
Application Due Dates: February 08, 2022
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research.

NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)

NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)
Application Due Date(s): October 12, 2021
This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences.

National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)
Application Due Date(s): October 28, 2021
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research 

National Program for the Career Development Of Physician Scientists in Diabetes Research (Diabetes - Docs) (K12 Clinical Trial Optional)
Application Due Dates: November 18, 2021
The purpose of the Diabetes-Docs Program is to support the career development of physicians committed to a career in diabetes research. The program is intended to remedy the dearth of pediatric endocrinologists and physicians from other specialties conducting innovative research into the causes and consequences of diabetes.

NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to application receipt date
Application Due Dates: November 15, 2021
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
Application Due Date(s): October 12, 2021
The purpose of the NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research.

Autism Centers of Excellence: Networks (R01 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: November 09, 2021
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and partnering Institutes invite applications for the Autism Centers of Excellence: Networks Program, hereafter termed “ACE Networks”. Each ACE Network will consist of a multi-site project focusing on a specific topic of research for R01 support through this FOA.

Learning Disabilities Innovation Hubs (P20 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to application receipt date
Application Due Dates: November 30, 2021
This funding opportunity announcement (FOA) invites exploratory grant applications, hereafter referred to as the Learning Disabilities Innovation Hubs or LD Hubs, addressing the etiology, manifestation, prevention and remediation of reading, writing and/or mathematics specific learning disorders (SLDs).

Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)
Application Due Date(s): September 25, 2021

Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
Application Due Date(s): September 25, 2021
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

Blueprint MedTech: Incubator Hubs (U54 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): September 20,2021
Application Due Dates: October 20, 2021
The Blueprint MedTech program is an NIH incubator that aims to accelerate the development of cutting-edge medical devices to diagnose and treat disorders of the nervous system. This FOA solicits centers ("incubator hubs") to coordinate and manage resources for the Blueprint MedTech program. Hubs will be responsible for providing innovators with resources to support development of human-grade prototypes.

Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
Letter of Intent Due Date(s): 60 days prior to the application due date.
Application Due Dates: October 20, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems.

HIV Prevention and Alcohol (R01 Clinical Trials Optional)
Letter of Intent Due Date(s): November 16, 2021
Application Due Dates: December 16, 2021

HIV Prevention and Alcohol (R34 Clinical Trials Optional)
Letter of Intent Due Date(s): November 16, 2021
Application Due Dates: December 16, 2021
The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.

Impact of Technology and Digital Media (TDM) Exposure/Usage on Child and Adolescent Development (P01 Clinical Trial Optional)
Letter of Intent Due Date(s): October 29, 2021
Application Due Dates: November 29, 2021
This funding opportunity announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs examining the pathways by which technology and digital media (TDM) exposure and usage impact developmental trajectories and health outcomes in early childhood (ages birth-8) and adolescence (ages 9-17).

Pediatric Centers of Excellence in Nephrology (P50 Clinical Trial Optional)
Letter of Intent Due Date(s): October 18, 2021
Application Due Dates: November 18, 2021
This Funding Opportunity Announcement (FOA) invites applications for the Pediatric Centers of Excellence in Nephrology (PCEN) to support basic, translational and clinical research in pediatric kidney disease.

HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: November 03, 2021
This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PD/PIs to investigate the mechanism of action of device-based pain relief with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies.

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: January 11, 2022
This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in priority areas in substance use epidemiology, prevention, and health services.

Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed)
Application Due Dates: October 16, 2021

Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
Application Due Dates: October 16, 2021
This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.